

- 39 -

## ABSTRACT OF THE DISCLOSURE

The present invention relates to crystalline and amorphous forms of repaglinide and the process for the preparation thereof. In particular, a new crystalline Form III of S-repaglinide is described and the process for its preparation is provided. Both the crystalline and amorphous forms of repaglinide are suitable for pharmaceutical purposes in the treatment of diabetes. The processes of the invention are simple, non-hazardous and commercially suitable.